Cysview® (hexaminolevulinate hydrochloride) is indicated as an adjunct to white-light cystoscopy in the detection of non-muscle invasive papillary bladder cancer, in patients with known or suspicion of bladder cancer.

Click here for Part III: Consumer Information of the Product Monograph

Ask your doctor or hospital about new tools to help detect
non-muscle invasive paillary bladder cancer. Ask your doctor if you are a suitable patient.

Hospitals Using Cysview®

  • Humber River Hospital (Toronto, ON)
  • Kingston General Hospital (Kingston, ON)

Check this page regularly for updates

Hospitals in the Process of Evaluating/Considering Cysview®

  • Centre universitaire de sante McGill (CUSM) - Glen Site (Montreal, QC)
  • University Health Network (UHN) - Toronto General Hospital, Princess Margaret Cancer Centre, and Mount Sinai Hospital (Toronto, ON)
  • University of Alberta (Edmonton, AB)
  • Vancouver General Hospital (Vancouver, BC)

In The News

Jan 20, 2017 -

March 24, 2017 - KGH Connect

April 5, 2017 -

Jan 25, 2018 -